LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy.

@article{Long2014LY294002ST,
  title={LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy.},
  author={Xin Hua Long and Z. H. Zhong and Ai Fen Peng and Liang Bo Zhu and Heng Wang and Guo Mei Zhang and Zhi Li Liu},
  journal={Molecular medicine reports},
  year={2014},
  volume={10 6},
  pages={2967-72}
}
Pirarubicin is frequently used in chemotherapy against tumors. However, clinical use is severely limited by the development of progressive dose-dependent cardiomyopathy and acquired drug resistance. LY294002 is a commonly used pharmacologic inhibitor, which selectively inhibits the phosphoinositide 3-kinase-AKT nexus. The aim of this study was to… CONTINUE READING